Cost-effectiveness analysis of different dipeptidyl-peptidase 4 inhibitor drugs for treatment of type 2 diabetes mellitus

Autor(es)

Cazarim, Maurilio de Souza ; Coelho da Cruz-Cazarim, Estael Luzia ; Baldoni, Andre de Oliveira ; Enes dos Santos, Thais Bueno ; de Souza, Paula Goncalves ; Silva, Ingrid de Almeida ; Reis Rodrigues, Roberta Niriam ; Franco Correa Maia, Alda Cristina ; Leira Pereira, Leonardo Regis ; Sanches, Cristina

• Tipo de documento: Artigo Científico
• Fonte: DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS; v. 11, p. 7-pg., 2017-12-01.

Resumo

Introduction: Type 2 diabetes mellitus (T2DM) has burdened health systems in the world to the value of 500 billion dollars/year. Dipeptidyl peptidase 4 inhibitors (DPP-4 Inhibitors) have been strongly associated with spending on the treatment of T2DM by the courts in Brazil. The aim of this study was to estimate the most cost-effective DPP-4 Inhibitor for T2DM treatment. A pharmacoeconomic study of cost-effectiveness was performed in a medium-sized municipality in Minas Gerais state, Brazil. Methods: The data are from legalization in municipal health in 2013. The effectiveness of DPP-4 Inhibitors was measured by the reduction in glycated hemoglobin (A1c). The direct medical costs of drug and adverse drug reactions were identified. With these data, a cost-effectiveness ratio (CER) and construction of the decision tree for sensitivity analysis were performed. Results: The representative of the most effective in reducing A1c gliptins was sitagliptin in combination with metformin, it was able to reduce A1c by 1.16% (1.09 to 1.22, CI 95%). The drug with the lowest cost was linagliptin, with a cost per patient/year of US$ 481.42. Sensitivity analysis performed by the decision tree shows that sitagliptin in association with metformin had the CER of US$ 1,506.75 per patient/year, to reduce A1c by 1%. Conclusion: The most cost-effective DPP-4 Inhibitor was sitagliptin with metformin. (C) 2017 Diabetes India. Published by Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 14/02087-9 - Avaliação econômica em longo prazo da atenção farmacêutica para pacientes com hipertensão arterial sistêmica
• Beneficiário: Maurilio de Souza Cazarim
• Modalidade de apoio: Bolsas no Brasil - Mestrado